PE20121702A1 - Proteinas de enlace cd127 - Google Patents
Proteinas de enlace cd127Info
- Publication number
- PE20121702A1 PE20121702A1 PE2012001071A PE2012001071A PE20121702A1 PE 20121702 A1 PE20121702 A1 PE 20121702A1 PE 2012001071 A PE2012001071 A PE 2012001071A PE 2012001071 A PE2012001071 A PE 2012001071A PE 20121702 A1 PE20121702 A1 PE 20121702A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdrh2
- cdrh3
- lysine
- residue
- Prior art date
Links
- 239000004472 Lysine Substances 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010038498 Interleukin-7 Receptors Proteins 0.000 abstract 1
- 102000010782 Interleukin-7 Receptors Human genes 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
REFERIDA A UN ANTICUERPO HUMANIZADO QUE COMPRENDE UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE UNA, DOS O TRES DE LAS SIGUIENTES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD: i) CDRH1 DE SEQ ID Nº:2, ii) CDRH2 DE SEQ ID Nº:3, iii) CDRH3 DE SEQ ID Nº:4 O UNA CDRH3 DE SEQ ID Nº: 132 - 137, DONDE EL ANTICUERPO COMPRENDE UN RESIDUO DE LISINA EN LA POSICION 66, UN RESIDUO DE LISINA EN LA POSICION 69, O UNA VALINA EN LA POSICION 71 DE LA REGION VARIABLE DE CADENA PESADA. TAMBIEN ESTA REFERIDA A UNA PROTEINA DE ENLACE, UN VECTOR, UNA CELULA HUESPED Y UNA COMPOSICION FARMACEUTICA. DICHOS ANTICUERPOS ACTUAN SOBRE EL RECEPTOR DE IL-7 HUMANO (CD127) Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES TALES COMO LA ESCLEROSIS MULTIPLE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29901010P | 2010-01-28 | 2010-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121702A1 true PE20121702A1 (es) | 2012-12-14 |
Family
ID=44320081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000247A PE20170687A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace a cd127 |
| PE2012001071A PE20121702A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace cd127 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000247A PE20170687A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace a cd127 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8940303B2 (es) |
| EP (1) | EP2528947A4 (es) |
| JP (1) | JP5850860B2 (es) |
| KR (1) | KR20130028055A (es) |
| CN (1) | CN102812046B (es) |
| AR (1) | AR080027A1 (es) |
| AU (1) | AU2011209713B2 (es) |
| BR (1) | BR112012018914A2 (es) |
| CA (1) | CA2787070A1 (es) |
| CL (1) | CL2012002081A1 (es) |
| CO (1) | CO6592067A2 (es) |
| CR (1) | CR20120404A (es) |
| EA (1) | EA023700B1 (es) |
| IL (1) | IL220899A (es) |
| MA (1) | MA34004B1 (es) |
| MX (1) | MX339083B (es) |
| MY (1) | MY160590A (es) |
| NZ (1) | NZ601271A (es) |
| PE (2) | PE20170687A1 (es) |
| PH (1) | PH12012501549A1 (es) |
| SG (1) | SG182590A1 (es) |
| TW (1) | TWI489996B (es) |
| UA (1) | UA104663C2 (es) |
| UY (1) | UY33202A (es) |
| WO (1) | WO2011094259A2 (es) |
| ZA (1) | ZA201205624B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3027071A1 (en) | 2011-01-14 | 2013-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| EP3207061A1 (en) | 2014-10-18 | 2017-08-23 | Pfizer Inc | Anti-il-7r antibody compositions |
| JP2018511346A (ja) | 2015-03-31 | 2018-04-26 | ブイエイチスクエアード リミテッド | ポリペプチド |
| WO2016156466A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| EP3399999A4 (en) * | 2016-01-07 | 2020-03-11 | The Schepens Eye Research Institute, Inc. | THERAPEUTICS FOR IMMUNE-INFLAMMATORY DISEASES OF THE EYE |
| ES2737307T3 (es) | 2016-02-29 | 2020-01-13 | Ose Immunotherapeutics | Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| RS61808B1 (sr) | 2016-12-09 | 2021-06-30 | Ose Immunotherapeutics | Antitela i polipeptidi usmereni protiv cd127 |
| MA51583A (fr) * | 2018-01-04 | 2020-11-11 | Avidity Biosciences Inc | Molécules d'acide nucléique hétéroduplex et leurs utilisations |
| WO2020154293A1 (en) * | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
| JP7702363B2 (ja) | 2019-06-21 | 2025-07-03 | ソリッソ ファーマシューティカルズ，インク． | 組成物 |
| CN114466864B (zh) | 2019-06-21 | 2024-12-27 | 索瑞索制药公司 | 多肽 |
| JP7680377B2 (ja) | 2019-06-21 | 2025-05-20 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| JP2025518164A (ja) | 2022-05-30 | 2025-06-12 | オセ イムノセラピューティクス | Ｉｌ７ｒモジュレーター活性のバイオマーカー |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024146960A1 (en) | 2023-01-06 | 2024-07-11 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| WO2024146955A1 (en) | 2023-01-06 | 2024-07-11 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| FI915911A7 (fi) * | 1989-06-15 | 1991-12-16 | Immunex Corp | Interleukiini-7-reseptoreja |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| CA2163032C (en) | 1993-06-03 | 2001-02-06 | John Landon | Antibody fragments in therapy |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| NZ301916A (en) * | 1994-12-23 | 1999-05-28 | Smithkline Beecham Corp | Monoclonal antibodies to il-5 for use as antagonists to il-5 related disorders |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| SK150298A3 (en) * | 1996-05-04 | 1999-04-13 | Zeneca Ltd | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
| IL131131A0 (en) | 1997-02-07 | 2001-01-28 | Merck & Co Inc | Synthetic hiv gag genes |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| US20030175884A1 (en) | 2001-08-03 | 2003-09-18 | Pablo Umana | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DE50015293D1 (de) * | 1999-04-13 | 2008-09-11 | Wilex Ag | Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| JP5291279B2 (ja) | 2000-09-08 | 2013-09-18 | ウニヴェルジテート・チューリッヒ | 反復モジュールを含む反復タンパク質の集合体 |
| US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| EP2298805A3 (en) | 2002-09-27 | 2011-04-13 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| JP4871126B2 (ja) | 2003-07-04 | 2012-02-08 | アフィボディ・アーベー | Ｈｅｒ２に対する結合親和性を有するポリペプチド |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
| WO2006014679A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform |
| WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
| JP5386364B2 (ja) | 2006-12-18 | 2014-01-15 | ジェネンテック， インコーポレイテッド | 抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用 |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| AU2009206724A1 (en) | 2008-01-22 | 2009-07-30 | Biogen Idec Ma Inc. | RON antibodies and uses thereof |
| TW201018482A (en) * | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
-
2011
- 2011-01-26 UY UY0001033202A patent/UY33202A/es not_active Application Discontinuation
- 2011-01-26 MA MA35147A patent/MA34004B1/fr unknown
- 2011-01-26 MY MYPI2012003394A patent/MY160590A/en unknown
- 2011-01-26 PH PH1/2012/501549A patent/PH12012501549A1/en unknown
- 2011-01-26 BR BR112012018914A patent/BR112012018914A2/pt not_active IP Right Cessation
- 2011-01-26 US US13/013,993 patent/US8940303B2/en not_active Expired - Fee Related
- 2011-01-26 AU AU2011209713A patent/AU2011209713B2/en not_active Ceased
- 2011-01-26 PE PE2017000247A patent/PE20170687A1/es not_active Application Discontinuation
- 2011-01-26 KR KR1020127022553A patent/KR20130028055A/ko not_active Abandoned
- 2011-01-26 WO PCT/US2011/022507 patent/WO2011094259A2/en not_active Ceased
- 2011-01-26 CN CN201180015856.0A patent/CN102812046B/zh not_active Expired - Fee Related
- 2011-01-26 EA EA201290589A patent/EA023700B1/ru not_active IP Right Cessation
- 2011-01-26 PE PE2012001071A patent/PE20121702A1/es not_active Application Discontinuation
- 2011-01-26 JP JP2012551247A patent/JP5850860B2/ja not_active Expired - Fee Related
- 2011-01-26 SG SG2012053138A patent/SG182590A1/en unknown
- 2011-01-26 UA UAA201209254A patent/UA104663C2/ru unknown
- 2011-01-26 NZ NZ601271A patent/NZ601271A/en not_active IP Right Cessation
- 2011-01-26 TW TW100102962A patent/TWI489996B/zh not_active IP Right Cessation
- 2011-01-26 CA CA2787070A patent/CA2787070A1/en not_active Abandoned
- 2011-01-26 EP EP11737543.6A patent/EP2528947A4/en not_active Withdrawn
- 2011-01-26 AR ARP110100251A patent/AR080027A1/es unknown
- 2011-01-26 MX MX2012008765A patent/MX339083B/es active IP Right Grant
- 2011-01-26 US US13/574,847 patent/US9150653B2/en not_active Expired - Fee Related
-
2012
- 2012-07-12 IL IL220899A patent/IL220899A/en not_active IP Right Cessation
- 2012-07-24 CO CO12124175A patent/CO6592067A2/es active IP Right Grant
- 2012-07-25 ZA ZA2012/05624A patent/ZA201205624B/en unknown
- 2012-07-26 CL CL2012002081A patent/CL2012002081A1/es unknown
- 2012-07-31 CR CR20120404A patent/CR20120404A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121702A1 (es) | Proteinas de enlace cd127 | |
| CL2012001096A1 (es) | Proteina de enlace a antigeno aislada que enlaza il-23, que comprende al menos tanto una region variable de cadena pesada como de cadena liviana que comprenden cdrs mutadas; acido nucleico, vector y celula hospedera que la codifican; composicion farmaceutica; y su uso para tratar enfermedades asociadas a il-23 en un paciente. | |
| EA201390993A1 (ru) | Антитела к cd38 | |
| EP4349868A3 (en) | Humanized and chimeric monoclonal antibodies to cd47 | |
| EA201891435A1 (ru) | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 | |
| CY1116728T1 (el) | Παραγοντες οι οποιοι επαγουν αποπτωση για την αντιμετωπιση καρκινου και ανοσολογικων και αυτοανοσων νοσηματων | |
| ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| EA201690310A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
| PE20141548A1 (es) | Anticuerpo anti-alfabeta tcr | |
| PE20110413A1 (es) | Anticuerpos neutralizantes de la glicoproteina b de citomegalovirus humano | |
| WO2012064792A3 (en) | Protein complexes for antigen binding and methods of use | |
| PE20171512A1 (es) | Anticuerpos anti-fap | |
| PE20142407A1 (es) | Formulacion de anticuerpos | |
| EA201000424A1 (ru) | Антитела к il-23 | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| MX2013011706A (es) | Proteinas novedosas de enlace a antigeno. | |
| CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
| EA201170204A1 (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
| UA113728C2 (xx) | Фармацевтична композиція, яка містить антитіло до pcsk9 людини | |
| JOP20190097A1 (ar) | الجلوبولينات المناعية واستخداماتها | |
| TR201905101T4 (tr) | Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. | |
| MX2015008534A (es) | COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS. | |
| CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
| PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) | |
| EA201291345A1 (ru) | Цитруллинированные гистоновые пептиды и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |